Beyond PEG: Re-Engineering stealth-polymers to do more than just hide

Area of Science:

• Nanomedicine
• Polymer Chemistry
• Immunology

Background:

• Polyethylene glycol (PEG) has been a dominant stealth material in nanomedicine for decades.
• Increasing environmental exposure has led to high prevalence of anti-PEG antibodies (over 70% in some populations).
• Anti-PEG antibodies cause accelerated blood clearance (ABC), complement activation-related pseudoallergy (CARPA), and reduced drug efficacy, notably with mRNA vaccines.

Purpose of the Study:

• To reframe the concept of 'stealth' in nanomedicine from bioinertness to an active, programmable interface.
• To review novel strategies for re-engineering the nanomedicine corona to overcome limitations of traditional PEGylation.
• To explore advanced polymer architectures and bio-inspired coatings for improved drug delivery performance.

Main Methods:

• Review of branched, bottlebrush, and statistical PEG architectures for antibody evasion.
• Analysis of dePEGylation strategies triggered by tumor microenvironment cues (pH, redox, enzymes, ROS).
• Examination of alternative stealth polymers (zwitterionic, polyglycerol, etc.) and degradable platforms (heparosan, PSA, etc.).
• Investigation of bio-inspired tropic coatings (hyaluronic acid, phosphocholine, etc.) for receptor-mediated targeting.

Main Results:

• Novel PEG architectures can evade pre-existing anti-PEG antibodies while maintaining regulatory familiarity.
• Triggered dePEGylation enables controlled drug release and improved therapeutic outcomes.
• Alternative polymers offer enhanced circulation, antioxidant properties, and immune tolerance.
• Degradable platforms ensure prolonged circulation with clean metabolic clearance.
• Bio-inspired coatings leverage endogenous receptors for targeted delivery and stealth.

Conclusions:

• Stealth in nanomedicine is evolving from passive bioinertness to an active, programmable interface.
• Innovative polymer design and bio-inspired strategies are crucial for overcoming PEG limitations.
• Future nanomedicines will feature dynamic coronas capable of sensing, responding, and targeting for optimized therapies.